Skip to main content

Advertisement

Log in

Gout in 2013

Imaging, genetics and therapy: gout research continues apace

  • Year in Review
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

In 2013, much progress has occurred in gout research. Imaging continues to help elucidate aspects of pathophysiology and now suggests that healing of erosions could occur when urate levels are reduced dramatically. New genetic loci associated with hyperuricaemia have been identified and management strategies for prophylaxis of gout flares continue to evolve.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Different imaging modalities reveal all aspects of gout pathology.

References

  1. Dalbeth, N. et al. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy. Arthritis Care Res. http://dx.doi.org/10.1002/acr.2205.

  2. Becker, M. A. et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann. Rheum. Dis. 72, 1469–1474 (2013).

    Article  CAS  Google Scholar 

  3. Dalbeth, N. et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann. Rheum. Dis. 68, 1290–1295 (2009).

    Article  CAS  Google Scholar 

  4. Thiele, R. G. & Schlesinger, N. Diagnosis of gout by ultrasound. Rheumatology 46, 1116–1121 (2007).

    Article  CAS  Google Scholar 

  5. Kottgen, A. et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat. Genet. 45, 145–154 (2013).

    Article  Google Scholar 

  6. Choi, H. K., De Vera, M. A. & Krishnan, E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 47, 1567–1570 (2008).

    Article  CAS  Google Scholar 

  7. Hollis-Moffatt, J. E. et al. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island, and Caucasian case–control sample sets. Arthritis Rheum. 60, 3485–3492 (2009).

    Article  Google Scholar 

  8. Mitha, E. et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE2 international, phase 3, randomized, placebo-controlled trial. Rheumatology 52, 1285–1292 (2013).

    Article  CAS  Google Scholar 

  9. Schlesinger, N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin. Arthritis Rheum. 42, 155–165 (2012).

    Article  CAS  Google Scholar 

  10. Liu-Bryan, R. & Terkeltaub, R. Evil humors take their toll as innate immunity makes gouty joints TREM-ble. Arthritis Rheum. 54, 383–386 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author wishes to thank R. Stuart (Northern Clinic, Auckland), N. Dalbeth and A. Doyle (University of Auckland), and Q. Reeves (Auckland District Health Board) for their assistance in providing images for Figure 1.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fiona M. McQueen.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

McQueen, F. Imaging, genetics and therapy: gout research continues apace. Nat Rev Rheumatol 10, 67–69 (2014). https://doi.org/10.1038/nrrheum.2013.164

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.164

  • Springer Nature Limited

This article is cited by

Navigation